NO311801B1 - Nye hydroksykarboksylsyre-derivater og deres anvendelse - Google Patents
Nye hydroksykarboksylsyre-derivater og deres anvendelse Download PDFInfo
- Publication number
- NO311801B1 NO311801B1 NO19984717A NO984717A NO311801B1 NO 311801 B1 NO311801 B1 NO 311801B1 NO 19984717 A NO19984717 A NO 19984717A NO 984717 A NO984717 A NO 984717A NO 311801 B1 NO311801 B1 NO 311801B1
- Authority
- NO
- Norway
- Prior art keywords
- alkyl
- acid derivatives
- hydroxycarboxylic acid
- compounds
- hydroxy
- Prior art date
Links
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 38
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 206010020772 Hypertension Diseases 0.000 claims description 7
- -1 alkylammonium ion Chemical class 0.000 claims description 5
- 239000011575 calcium Substances 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 150000001768 cations Chemical class 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 3
- 201000006474 Brain Ischemia Diseases 0.000 claims description 3
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000033626 Renal failure acute Diseases 0.000 claims description 3
- 201000011040 acute kidney failure Diseases 0.000 claims description 3
- 208000012998 acute renal failure Diseases 0.000 claims description 3
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 3
- 238000002399 angioplasty Methods 0.000 claims description 3
- 206010008118 cerebral infarction Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 208000037803 restenosis Diseases 0.000 claims description 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 229910052788 barium Inorganic materials 0.000 claims description 2
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 229910052744 lithium Inorganic materials 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 230000036454 renin-angiotensin system Effects 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 63
- 239000000203 mixture Substances 0.000 description 30
- 238000012360 testing method Methods 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 102000002045 Endothelin Human genes 0.000 description 17
- 108050009340 Endothelin Proteins 0.000 description 17
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 17
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- 239000012074 organic phase Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 10
- 101800004490 Endothelin-1 Proteins 0.000 description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 102100033902 Endothelin-1 Human genes 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- RJUDROONFFKPJA-UHFFFAOYSA-N 2-hydroxy-3,3-diphenylbutanenitrile Chemical compound C=1C=CC=CC=1C(C(O)C#N)(C)C1=CC=CC=C1 RJUDROONFFKPJA-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 150000002825 nitriles Chemical class 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 102000010180 Endothelin receptor Human genes 0.000 description 4
- 108050001739 Endothelin receptor Proteins 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 208000001647 Renal Insufficiency Diseases 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- XQYZCPRMUQDJTD-UHFFFAOYSA-N ethyl 2-hydroxy-3,3-diphenylbutanoate Chemical compound C=1C=CC=CC=1C(C)(C(O)C(=O)OCC)C1=CC=CC=C1 XQYZCPRMUQDJTD-UHFFFAOYSA-N 0.000 description 4
- 201000006370 kidney failure Diseases 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- NQCFFHSZJWFYEU-UHFFFAOYSA-N 2,2-diphenylbutanenitrile Chemical compound C=1C=CC=CC=1C(C#N)(CC)C1=CC=CC=C1 NQCFFHSZJWFYEU-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- YYWJWHMVTAKKNT-UHFFFAOYSA-N 2-hydroxy-3,3-diphenylbutanamide Chemical compound C=1C=CC=CC=1C(C(O)C(N)=O)(C)C1=CC=CC=C1 YYWJWHMVTAKKNT-UHFFFAOYSA-N 0.000 description 3
- INQIVJHBJNZHFC-UHFFFAOYSA-N 2-hydroxy-3,3-diphenylbutanoic acid Chemical compound C=1C=CC=CC=1C(C(O)C(O)=O)(C)C1=CC=CC=C1 INQIVJHBJNZHFC-UHFFFAOYSA-N 0.000 description 3
- MVPIGSZIAQITKP-UHFFFAOYSA-N 2-hydroxy-3,3-diphenylpentanenitrile Chemical compound C=1C=CC=CC=1C(C(O)C#N)(CC)C1=CC=CC=C1 MVPIGSZIAQITKP-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 150000003862 amino acid derivatives Chemical class 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- ILIMURZDNWIXFH-UHFFFAOYSA-N methyl 2-hydroxy-3,3-diphenylbutanoate Chemical compound C=1C=CC=CC=1C(C)(C(O)C(=O)OC)C1=CC=CC=C1 ILIMURZDNWIXFH-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- JCRVIOGXBGOFER-UHFFFAOYSA-N 2,2-diphenylbutanal Chemical compound C=1C=CC=CC=1C(C=O)(CC)C1=CC=CC=C1 JCRVIOGXBGOFER-UHFFFAOYSA-N 0.000 description 2
- HMMWEJUBAXMERM-UHFFFAOYSA-N 2,2-diphenylpropanal Chemical compound C=1C=CC=CC=1C(C=O)(C)C1=CC=CC=C1 HMMWEJUBAXMERM-UHFFFAOYSA-N 0.000 description 2
- SENJWHDSFNFQAS-UHFFFAOYSA-N 2-(4,6-dimethoxypyrimidin-2-yl)oxy-3,3-diphenylbutanoic acid Chemical compound COC1=CC(OC)=NC(OC(C(O)=O)C(C)(C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 SENJWHDSFNFQAS-UHFFFAOYSA-N 0.000 description 2
- KOUPJFIOXPKOAY-UHFFFAOYSA-N 2-(4,6-dimethoxypyrimidin-2-yl)oxy-3,3-diphenylpentanenitrile Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(CC)C(C#N)OC1=NC(OC)=CC(OC)=N1 KOUPJFIOXPKOAY-UHFFFAOYSA-N 0.000 description 2
- IUOKTIGWXRJRIQ-UHFFFAOYSA-N 2-(4,6-dimethylpyrimidin-2-yl)oxy-3,3-diphenylbutanoic acid Chemical compound CC1=CC(C)=NC(OC(C(O)=O)C(C)(C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 IUOKTIGWXRJRIQ-UHFFFAOYSA-N 0.000 description 2
- SYBYTAAJFKOIEJ-UHFFFAOYSA-N 3-Methylbutan-2-one Chemical compound CC(C)C(C)=O SYBYTAAJFKOIEJ-UHFFFAOYSA-N 0.000 description 2
- ITDVJJVNAASTRS-UHFFFAOYSA-N 4,6-dimethoxy-2-methylsulfonylpyrimidine Chemical compound COC1=CC(OC)=NC(S(C)(=O)=O)=N1 ITDVJJVNAASTRS-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229940118365 Endothelin receptor antagonist Drugs 0.000 description 2
- 102100040611 Endothelin receptor type B Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010062575 Muscle contracture Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- VIROVYVQCGLCII-UHFFFAOYSA-N amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- KMPWYEUPVWOPIM-KODHJQJWSA-N cinchonidine Chemical compound C1=CC=C2C([C@H]([C@H]3[N@]4CC[C@H]([C@H](C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-KODHJQJWSA-N 0.000 description 2
- KMPWYEUPVWOPIM-UHFFFAOYSA-N cinchonidine Natural products C1=CC=C2C(C(C3N4CCC(C(C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-UHFFFAOYSA-N 0.000 description 2
- 208000006111 contracture Diseases 0.000 description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Chemical class CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 2
- 239000002308 endothelin receptor antagonist Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 208000001286 intracranial vasospasm Diseases 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- AGJSNMGHAVDLRQ-HUUJSLGLSA-N methyl (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,3-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate Chemical class SC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(=O)OC)CC1=CC=C(O)C(C)=C1C AGJSNMGHAVDLRQ-HUUJSLGLSA-N 0.000 description 2
- FARIWNRWUHAAIK-UHFFFAOYSA-N methyl 2-(4,6-dimethoxypyrimidin-2-yl)oxy-3,3-diphenylbutanoate Chemical compound C=1C=CC=CC=1C(C)(C=1C=CC=CC=1)C(C(=O)OC)OC1=NC(OC)=CC(OC)=N1 FARIWNRWUHAAIK-UHFFFAOYSA-N 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical class C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 2
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000025033 vasoconstriction Effects 0.000 description 2
- FMCAFXHLMUOIGG-JTJHWIPRSA-N (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-JTJHWIPRSA-N 0.000 description 1
- PGLASKORVDVZEZ-UHFFFAOYSA-N (2z)-1-cycloundecyl-2-diazocycloundecane Chemical compound [N-]=[N+]=C1CCCCCCCCCC1C1CCCCCCCCCC1 PGLASKORVDVZEZ-UHFFFAOYSA-N 0.000 description 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 1
- CYSGHNMQYZDMIA-UHFFFAOYSA-N 1,3-Dimethyl-2-imidazolidinon Chemical compound CN1CCN(C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- RTCUCQWIICFPOD-UHFFFAOYSA-N 1-naphthalen-1-ylethanamine Chemical compound C1=CC=C2C(C(N)C)=CC=CC2=C1 RTCUCQWIICFPOD-UHFFFAOYSA-N 0.000 description 1
- KHSYYLCXQKCYQX-UHFFFAOYSA-N 1-naphthalen-2-ylethanamine Chemical compound C1=CC=CC2=CC(C(N)C)=CC=C21 KHSYYLCXQKCYQX-UHFFFAOYSA-N 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- NEBPTMCRLHKPOB-UHFFFAOYSA-N 2,2-diphenylacetonitrile Chemical compound C=1C=CC=CC=1C(C#N)C1=CC=CC=C1 NEBPTMCRLHKPOB-UHFFFAOYSA-N 0.000 description 1
- DPVHBXFSKLKYIQ-UHFFFAOYSA-N 2,2-diphenylpropanenitrile Chemical compound C=1C=CC=CC=1C(C#N)(C)C1=CC=CC=C1 DPVHBXFSKLKYIQ-UHFFFAOYSA-N 0.000 description 1
- VOBNLAZLBAVMFT-UHFFFAOYSA-N 2-(4,6-dimethoxypyrimidin-2-yl)oxy-3,3-diphenylpentanoic acid Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(CC)C(C(O)=O)OC1=NC(OC)=CC(OC)=N1 VOBNLAZLBAVMFT-UHFFFAOYSA-N 0.000 description 1
- IOXOZOPLBFXYLM-UHFFFAOYSA-N 2-(4-nitrophenyl)ethanamine Chemical class NCCC1=CC=C([N+]([O-])=O)C=C1 IOXOZOPLBFXYLM-UHFFFAOYSA-N 0.000 description 1
- OFQCQIGMURIECL-UHFFFAOYSA-N 2-[2-(diethylamino)ethyl]-2',6'-dimethylspiro[isoquinoline-4,4'-oxane]-1,3-dione;phosphoric acid Chemical compound OP(O)(O)=O.O=C1N(CCN(CC)CC)C(=O)C2=CC=CC=C2C21CC(C)OC(C)C2 OFQCQIGMURIECL-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 1
- ZMGMDXCADSRNCX-UHFFFAOYSA-N 5,6-dihydroxy-1,3-diazepan-2-one Chemical compound OC1CNC(=O)NCC1O ZMGMDXCADSRNCX-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010049993 Cardiac death Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 102400000686 Endothelin-1 Human genes 0.000 description 1
- 102100029110 Endothelin-2 Human genes 0.000 description 1
- 108090000387 Endothelin-2 Proteins 0.000 description 1
- 102100029109 Endothelin-3 Human genes 0.000 description 1
- 108010072844 Endothelin-3 Proteins 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 238000006546 Horner-Wadsworth-Emmons reaction Methods 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 229940078123 Ras inhibitor Drugs 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 238000007059 Strecker synthesis reaction Methods 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
- JVVXZOOGOGPDRZ-SLFFLAALSA-N [(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl]methanamine Chemical compound NC[C@]1(C)CCC[C@]2(C)C3=CC=C(C(C)C)C=C3CC[C@H]21 JVVXZOOGOGPDRZ-SLFFLAALSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960001301 amobarbital Drugs 0.000 description 1
- 229940072049 amyl acetate Drugs 0.000 description 1
- PGMYKACGEOXYJE-UHFFFAOYSA-N anhydrous amyl acetate Natural products CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- RRKTZKIUPZVBMF-IBTVXLQLSA-N brucine Chemical compound O([C@@H]1[C@H]([C@H]2C3)[C@@H]4N(C(C1)=O)C=1C=C(C(=CC=11)OC)OC)CC=C2CN2[C@@H]3[C@]41CC2 RRKTZKIUPZVBMF-IBTVXLQLSA-N 0.000 description 1
- RRKTZKIUPZVBMF-UHFFFAOYSA-N brucine Natural products C1=2C=C(OC)C(OC)=CC=2N(C(C2)=O)C3C(C4C5)C2OCC=C4CN2C5C31CC2 RRKTZKIUPZVBMF-UHFFFAOYSA-N 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229960003609 cathine Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- BVURNMLGDQYNAF-UHFFFAOYSA-N dimethyl(1-phenylethyl)amine Chemical class CN(C)C(C)C1=CC=CC=C1 BVURNMLGDQYNAF-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical compound [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- DZNKOAWEHDKBEP-UHFFFAOYSA-N methyl 2-[6-[bis(2-methoxy-2-oxoethyl)amino]-5-[2-[2-[bis(2-methoxy-2-oxoethyl)amino]-5-methylphenoxy]ethoxy]-1-benzofuran-2-yl]-1,3-oxazole-5-carboxylate Chemical compound COC(=O)CN(CC(=O)OC)C1=CC=C(C)C=C1OCCOC(C(=C1)N(CC(=O)OC)CC(=O)OC)=CC2=C1OC(C=1OC(=CN=1)C(=O)OC)=C2 DZNKOAWEHDKBEP-UHFFFAOYSA-N 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- RCSSHZGQHHEHPZ-UHFFFAOYSA-N n-methyl-1-phenylethanamine Chemical class CNC(C)C1=CC=CC=C1 RCSSHZGQHHEHPZ-UHFFFAOYSA-N 0.000 description 1
- MYWUZJCMWCOHBA-UHFFFAOYSA-N n-methyl-1-phenylpropan-2-amine Chemical compound CNC(C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-UHFFFAOYSA-N 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical class CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 1
- 229960000317 yohimbine Drugs 0.000 description 1
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/20—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with no nitrogen atoms directly attached to a ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/30—Only oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/38—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/48—Two nitrogen atoms
- C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
Foreliggende oppfinnelse angår nye a-hydroksykarboksylsyre-derivater og
deres anvendelse.
Endotelin er et peptid som er oppbygget av 21 aminosyrer og syntetiseres og frigis av vaskulær endotel. Endotelin eksisterer i tre isoformer, ET-1, ET-2 og ET-3. I det følgende betyr «endotelin» eller «ET» én eller alle isoformer av endotelin. Endotelin er ein sterk vasokonstriktor og har en sterk effekt på kar-tonusen. Det er kjent at denne vasokonstriksjon forårsakes av bindingen av endotelin på dets reseptor (Nature, 332, 411-415, 1988; FEBS Letters, 231, 440-444, 1988 og Biochem. Biofys. Res. Commun., 154, 868-875, 1988).
Forhøyet eller abnormal frigjøring av endotelin forårsaker en vedvarende kar-kontraksjon i perifere, renale og cerebrale blodkar, noe som kan føre til sykdommer. Som angitt i litteraturen er endotelin involvert i en rekke sykdommer, så som hypertoni, myokardinfarkt, hjertesvikt, nyresvikt, pulmonær hypertoni, Raynaud-syndrom, cerebrale vasospasmer, aterosklerose, slaganfall, benign prostatahypertrofi og astma (Japan J. Hypertension 12, 79 (1989), J. Vascular Med. Biology 2, 207
(1990), J. Am. Med. Association 264, 2868 (1990), Nature 344, 11 (1990), N. Engl. J.
Med, 322, 205 (1989), N. Engl. J. Med. 328,1732 (1993), Nefron 66, 373 (1994), Strake 25, 904 (1994), Nature 365, 759 (1993), J. Mol. Cell. Cardiol. 27, A234 (1995), Cancer Research 56, 663 (1996).
En forbindelse som har formel A
er nevnt i den europeiske patentsøknad P 44 36 851,8 (side 32, forbindelse I-28). Denne forbindelse kan imidlertid ikke fremstilles ved den fremstillingsprosess som er nevnt i denne patentsøknad.
Forbindelser med formelen B hvor R3 kan være for eksempel fenyl og R2 og R<4 >kan være hydrogen eller CrC4-alkyl, er beskrevet i europeisk patent nr. 0 347 811 B1 som susbtanser med herbicid virkning.
Gjenstand for oppfinnelsen er a-hydroksykarboksylsyre-derivatene med formel I hvor R står for eksempel for en gruppe
hvor R<1> betyr en rest OR10, hvor R<10> er:
hydrogen, kationet av et alkalimetall så som litium, natrium, kalium, eller
kationet av et jordalkalimetall så som kalsium, magnesium og barium, samt
fysiologisk akseptabelt alkylammoniumion eller ammoniumionet, C3-C8-cykloalkyl;
Ci-Cs-alkyl;
CH2-fenyl,
W betyr nitrogen;
R<2> er Ci-C4-alkyl, CrC4-alkoksy,
X er nitrogen eller CH;
R<3> kan være hydrogen, C1-C4 - alkyl, CrC4 - alkoksy eller CF3; og R2 og R3 kan
være like eller forskjellige;
Y er nitrogen;
R<4> erfenyl;
R<5> kan ha den samme betydning som R<4>;
R<6> er eventuelt med hydroksy substituert Ci-C8-alkyl, eller
Forbindelsene og også mellomproduktene for deres fremstilling II, kan ha ett eller flere asymmetriske substituerte karbonatomer. Slike forbindelser kan foreligge i form av de rene enantiomerer eller rene diastereomerer eller som blandinger av disse. Foretrukket er anvendelsen av en enantiomer-ren forbindelse som virkestoff.
Gjenstand for oppfinnelsen er videre anvendelsen av de ovenfor nevnte karb-oksylsyrederivater for fremstilling av legemidler, særlig for fremstilling av hemmende preparater for endotelin-reseptorer.
Forbindelsene ifølge oppfinnelsen blir fremstilt ved omsetning av et hydroksy-karboksylsyrederivat II hvor substituentene har den angitte betydning, med forbindelser med den generelle formel III,
hvor R<17> betyr halogen eller R<18> -S02-, hvor R<18> kan være CrC4-alkyl, Ci-C4-halogenalkyl eller fenyl.
Reaksjonen finner fortrinnsvis sted i et inert fortynningsmiddel under tilsetning av en egnet base, dvs. en base som deprotonerer mellomproduktet II, ved en temperatur i området fra romtemperatur til kokepunktet for løsemidlet.
Eksempler på slike løsemidler eller fortynningsmidler er vann, alifatiske, alicykliske og aromatiske hydrokarboner, som i hvert tilfelle eventuelt kan være klorert, som foreksempel heksan, cykloheksan, petroleter, ligroin, benzen, toluen, xylen, metylenklorid, kloroform, karbontetraklorid, etylklorid og trikloretylen; etere, som foreksempel diisopropyleter, dibutyleter, metyl-tert.-butyleter, propylenoksyd, dioksan og tetrahydrofuran; ketoner, som foreksempel aceton, metyletylketon, metylisopropylketon og metylisobutylketon; nitriler, som foreksempel acetonitril og propionitril; alkoholer, som for eksempel metanol, etanol, isopropanol, butanol og etylenglykol; estere, som for eksempel etylacetat og amylacetat; syreamider, som for eksempel dimetylformamid og dimetylacetamid; sulfoksyder og sulfoner, som for eksempel dimetylsulfoksyd og sulfolan; baser, som for eksempel pyridin, N-metylpyrrolidon; cykliske ureatyper som 1,3-dimetylimidazolidin-2-on og 1,3-dimetyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinon.
Reaksjonen utføres fortrinnsvis ved en temperatur i området fra 0°C til kokepunktet for løsemidlet eller blandingen av løsemidler.
Som base kan det anvendes et alkali- eller jordalkalimetallhydrid som natriumhydrid, kaliumhydrid eller kalsiumhydrid, et karbonat som alkalimetallkar-bonat, f.eks. natrium- eller kaliumkarbonat, et alkali- eller jordalkalimetallhydroksyd som natrium- eller kaliumhydroksyd, en metallorganisk forbindelse som butyllitium eller et alkaliamid som litiumdiisopropylamid eller litiumamid eller tertiære aminer, f.eks. trietylamin, pyridin, 4-N,N-dimetylaminopyridin, imidazol eller diazo-bicykloundekan.
Forbindelser med formel II kan fremstilles på kjent måte.
For eksempel kan forbindelser med formel II kan fremstilles ved overføring av et nitril med formel IV i et nitril V ved alkylering ved hjelp av en base og en forbindelse R<6->K,
som for eksempel beskrevet i Ca. J. of Chem. 47 (1969) 1587 ff, hvor K er en utgående gruppe så som halogen, tosylat, mesylat eller triflat.
Nitrilene V blir deretter redusert til aldehyder VI som beskrevet i Synth. Comm.
19 (1989) 355 ff. eller J. Am. Chem. Soc. 107 (1985) 4577 ff. Reduksjonsmidler som kan anvendes er metallhydrider så som LiAIH4 eller (n-Bu)2A1H.
Aldehydene VI omdannes ved kjente metoder (som beskrevet, for eksempel i Chem. Pharm. Bull. 37(1989) 2570-2), i de tilsvarende cyanohydriner VII: Cyanohydriner VII kan ved hydrolyse, for eksempel med vandig HCI eller ved hjelp av Pinner-metoden med HCI-gass i alkohol R<10>OH, overføres i a-hydrok-sykarboksylsyrederivater II hvor
Forbindelser II kan også fremstilles ved diazotering av et aminosyrederivat VIII ved kjente metoder, f.eks. med natriumnitritt og vandig svovelsyre og hydrolysering til hydroksysyrederivatet II som for eksempel beskrevet i Syntese (1987), 479-80.
Aminosyrederivater VIII kan for eksempel fremstilles i en Strecker-reaksjon fra aldehydene VI, f.eks. som beskrevet i Angew. Chem. Int. Ed. 26 (1987), 557 ff.
Dessuten kan forbindelser VIII fremstilles ved omsetning av en forbindelse IX med en Grignard-forbindelse X og hydrolysering av produktet XI med syre til VIII, som beskrevet i Liebigs Ann. (1977) 1174-1182: Forbindelser II kan videre syntetiseres ved elektrofil oksydasjon av karboksyl-syrederivater XII, f.eks. med oksygen etter deprotonering, som beskrevet i Tetrahedron Letters 21 (1975) 1731-4 eller med Davis-reagens
som beskrevet i J. Org. Chem. 47 (1982) 1775-77.
Forbindelser XII kan fremstilles ved omsetning av en egnet fosfonatforbindelse XIII med en karbonylforbindelse XIV i en Wittig-Horner-reaksjon til umettet forbindelse XV.
Forbindelse XV kan deretter ved en metode fra Chem. Ber. 64 (1931) 1493 ff. med R<5->H i nærvær av en Friedel-Crafts-katalysator så som aluminumtriklorid omdannes til karboksylsyrederivatet XVI.
Forbindelser I kan også fremstilles ved omsetning av cyanohydrin VII med forbindelser III til nitriler XVII.
Reaksjonen finner fortrinnsvis finner sted et inert løsemiddel under tilsetning av en egnet base som beskrevet tidligere.
Forbindelser XVII kan deretter omdannes på kjent måte, for eksempel ved omsetning med syrer så som saltsyre eller svovelsyre, med eller uten tilsetning av alkoholer, til forbindelser av type I.
Forbindelser med formel I kan oppnås i enantiomer-ren form ved å starte fra enantiomere forbindelser II, som kan fremstilles ved klassisk racematspaltning eller ved enantioselektive synteser (som for eksempel Ren Appl. Chem., 55 (1983) 1799 et ff.; Heiv. Chim. Acta, 71 (1988) 224 et ff.; J. Am. Chem. Soc, f 70(1988) 1547-1557; Chem. Eng. News (1989) 25-27) i enantiomer-ren og eventuelt diastereomer-ren form og omsetning av disse forbindelser II med III som beskrevet ovenfor. En annen mulighet for å oppnå enantiomer-rene forbindelser med formel I er klassisk racematspaltning av racemiske eller diastereomere forbindelser I med egnede enantiomer-rene baser som f.eks. brucin, stryknin, kinin, kinidin, kinchonidin, kinchonin, yohimbin, morfin, dehydroabietylamin, efedrin (-), (+), deoksyefedrin (+), (-), threo-2-amino-1-(p-nitrofenyl)-1,3-propandiol (+), (-), threo-2-(N,N-dimetylamino)-1-(p-nitrofenyl)-1,3-propandiol (+), (-) threo-2-amino-1-fenyl-1,3-propandiol (+), (-), a-metylbenzylamin (+), (-), a-(1-naftyl)etylamin (+), (-), a-(2-naftyl)etylamin (+), (-), aminometylpinon, N,N-dimetyl-1-fenyletylamin, N-metyl-1-fenyletylamin, 4-nitrofenyletylamin, pseudoefedrin, norefedrin, norpseudoefedrin, aminosyrederivater og peptidderivater.
Foretrukne forbindelser med formel I, både som rene enantiomerer og rene diastereomerer eller som blanding derav, er de hvor
R er en karboksylsyre,
slike hvori R6 betyr Ci-C8-alkyl, eventueltsubstituert med OH, slike hvori X betyr CH, og slike hvori minst én av restene R<2>, R<3> betyr CrC4-alkyl.
Forbindelsene ifølge foreliggende oppfinnelse tilveiebringer et nytt terapeutisk potential for behandlingen av hypertoni, pulmonalt høytrykk, myokardinfarkt, angina pectoris, akutt nyresvikt, nyreinsuffisiens, cerebrale vasospasmer, zerebral iskemi, subaraknoidalblødninger, migrene, astma, aterosklerose, endotoksisk sjokk, endotoksinindusert organsvikt, intravaskulær koagulasjon, restenose etter angioplasti, benign prostata-hyperplasi, iskemisk nyresvikt og nyresvikt forårsaket av intoksikasjon eller hypertoni, samt kreftsykdommer, og særlig prostatakrebs og hudkreft.
Den gode virkning av forbindelsene lar seg vise i de følgende forsøk:
Reseptorbindingsstudier
For bindungsstudier ble klonede humane ETA-reseptor-uttrykkende CHO-celler og marsvin-lillehjerne-membraner med > 60 % ETB sammenliknet med ETA-reseptorer.
Membranpreparering
De ETA-reseptor-uttrykkende CHO-celler fikk formere seg i Fi2-medium med 10 % føtalt kalveserum, 1 % glutamin, 100 E/ml penicillin og 0,2 % streptomycin (Gibco BRL, Gaithersburg, MD, USA). Etter 48 timer ble cellene vasket med PBS og inkubert med 0,05 % trypsinholdig PBS i 5 min. Deretter ble det nøytralisert med Fi2-medium og cellene ble samlet ved sentrifugering ved 300 x g. For lysis av cellene ble pelleten kort vasket med lysis-buffer (5 mM tris-HCI, pH 7,4 med 10 % glycerol) og deretter inkubert i en konsentrasjon på 10<7> celler/ml lysisbuffer i 30 min. ved 4°. Membranene ble sentrifugert ved 20 000 x g i 10 min. og pelleten lagret i flytende nitrogen.
Marsvin-lillehjemer ble homogenisert i en Potter-Elvejhem-homogenisator og utvunnet ved differensiell sentrifugering i 10 min. ved 1 000 x g og gjentatt sentrifugering av det overstående i 10 min. ved 20 000 x g.
Bindingstester
For ETA- og ETe-reseptorbindingstesten ble membranene suspendert i inkubasjonsbuffer (50 mM tris-HCI, pH 7,4 med 5 mM MnCI2, 40 ug/ml bacitracin og 0,2 % BSA) i en konsentrasjon på 50 ug protein pr. testblanding og inkubert ved 25°C med 25 pM [125JJ-ET"! (ETA-reseptortest) eller 25 pM [125J]-RZ3 (ETB-reseptortest) i nærvær og i fravær av testsubstans. Den ikke-spesifikke binding ble bestemt med 10"<7> M ETV Etter 30 min. ble den frie og den bundne radioligand fraskilt ved filtrering over GF/B glassfiberfilter (Whatman, England) på en Skatron-cellesamler (Skatron, Lier, Norge) og filtrene ble vasket med iskald tris-HCI-buffer, pH 7,4 med 0,2 % BSA. Den radioaktivitet som var samlet på filtrene ble kvantifisert med en Packard 2200 CA væske-scincillasjonsteller.
Funksjonelt in vitro testsystem for å søke etter endotelinreseptor (subtype A)-antagonister
Dette testsystem er en funksjonell, cellebasert test for endotelinreseptorer. Bestemte celler viser, dersom de blir stimulert med endotelin 1 (ET1), en stigning i den intracellulære kalsiumkonsentrasjon. Denne stigning kan måles i intakte celler som er belastet med kalsium-sensitive farvestoffer.
1-Bindevevsceller som var blitt isolert fra rotter og hvor det var blitt påvist en_ endogen endotelinreseptor av A-subtype, ble belastet med fluorescensfarvestoffet Fura 2-an som følger: Etter trypsinering ble cellene resuspendert i buffer A (120 mM
NaCI, 5 mM KCI, 1,5 mM MgCI2, 1 mM CaCI2, 25 mM HEPES, 10 mM glukose, pH 7,4) inntil en densitet på 2 x 10<6>/ml og inkubert i 30 min. ved 37°C i mørke med Fura 2-am (2 uM), Pluronics F-127 (0,04 %) og DMSO (0,2 %). Deretter ble cellene vasket to ganger med buffer A og resuspendert til 2 x 10<6>/ml.
Fluorescens-signaletfra 2 x 10<5> celler pr. ml ved Ex/Em 380/510 ble ved 30°C registrert kontinuerlig. Testsubstansene ble satt til cellene, og etter en inku-basjonstid på 3 min. ET1 ble den maksimale endring i fluorescensen bestemt. Cellenes respons på ET1 uten tilsetning av en testsubstans på forhånd tjente som kontroll og ble satt lik 100 %.
Testing av ET-antagonister i vivo
Mannlige SD-rotter med vekt 250 - 300 g ble narkotisert med amobarbital, fikk kunstig åndedrett, og ble vagotomisert og despinalisert. Arteria carotis og vena jugularis ble katetisert.
I kontrolldyr fører intravenøs administrering av 1 ug/kg ET1 til en tydelig blodtrykkstigning, som bibeholdes over et lengre tidsrom.
Testdyrene fikk en i.v.-injeksjon av testforbindelsene (1 ml/kg) 5 min. før administrering av ET1. For bestemmelse av de ET-antagonistiske egenskaper ble blodtrykkstigningen i testdyrene sammenliknet med blodtrykkstigningen i kontroll-dyrene.
Endotelin-1-indusert »plutselig død» for mus
Testprinsippet besetår i hemning av den plutselige hjertedød for mus forårsaket av endotelin, og som sannsynligvis er betinget av sammentrekning av koro-narkarene, ved forbehandling med endotelin-reseptorantagonister. Etter intravenøs injeksjon av 10 nmol/kg endotelin i et volum på 5 ml/kg kroppsvekt dør dyrene i løpet av få minutter.
Den letale endotelin-1-dosis etterprøves i hvert tilfelle på et lite dyrekollektiv. Dersom testsubstansen administreres intravenøst, finner i de fleste tilfeller den for kontrollgruppen letale endotelin-1-injeksjon sted 5 minutter senere. Ved andre administreringsmåter forlenges tidene før administrering, eventuelt opptil flere timer.
Overlevelsesgraden noteres og den effektive dose, som beskytter 50 % av — dyrene (ED 50) i 24 timer eller lenger mot endotelin-indusert hjertedød, blir bestemt.
Funksjonell kartest for endotelin-reseptorantagonister
På aortasegmenter fra kanin blir det etter en for-spenning på 2 g og en relaksasjonstid på 1 time i Krebs-Henseleit-løsning ved 37°C og en pH-verdi mellom. 7,3 og 7,4 først utløst en K<+->kontraktur. Etter utvasking blir det laget en endotelin-dosisvirkningskurve opptil maksimum.
Potensielle endotelin-antagonister blir administrert til andre preparater i det samme kar 15 minutter før begynnelsen av endotelin-dosisvirkningskurven. Virk-ningene av endotelinet blir beregnet i % av K<+->kontrakturen. Ved virksomme endotelin-antagonister opptrer høyreforskyvning av endotelin-dosisvirkningskurven.
Forbindelsene ifølge oppfinnelsen kan på vanlig måte administreres oralt eller parenteralt (subkutant, intravenøst, intramuskulært, intraperotonealt). Administrering kan også finne sted med damper eller spray gjennom nese-hals-området.
Doseringen avhenger av pasientens alder, tilstand og vekt, samt av admi-nistreringsmåten. Vanligvis utgjør den daglige virkestoffdosis mellom ca. 0,5 og 50 mg/kg legemsvekt ved oral administrering og mellom ca. 0,1 og 10 mg/kg legemsvekt ved parenteral administrering.
De nye forbindelser kan anvendes i de vanlige galeniske faste eller flytende former, f.eks. som tabletter, filmtabletter, kapsler, pulvere, granulater, dragéer, suppositorier, løsninger, salver, kremer eller spray. Disse fremstilles på vanlig måte. Virkestoffene kan bearbeides med de vanllige galeniske hjelpemidler så som tablett-bindemidler, fyllstoffer, konserveringsmidler, tablett-sprengmidler, flytreguleringsmidler, myknere, fuktemidler, dispergeringsmidler, emulgatorer, løse-midler, retarderingsmidler, antioksydanter og/eller drivgasser (se. H. Sucker et al.: Pharmazeutische Technologie, Thieme-Verlag, Stuttgart, 1991). De således oppnådde anvendelsesformer inneholder normalt virkestoffet i en mengde på 0,1 til 90 vekt%.
Oppfinnelsen angår videre kombinasjonen av forbindelser med formel I med inhibitorer av renin-angiotensin-systemet (RAS). RAS-inhibitorer er beskrevet i for eksempel EP 634 175.
Kombinasjonene er egnet for behandling av slike sykdommer somogså forbindelser med formel I alene er virksomme mot, spesielt for behandling av hypertoni og kronisk hjertesvikt.
Syntese-eksempler
Eksempel 1
2,2-Difenylpropionaldehyd
50,0 g (0,241 mol) 2,2-difenylpropionitril ble oppløst i 200 ml absolutt dietyleter og 74,2 ml av en én-molar løsning av LiAIH4 i eter ble tilsatt dråpevis. Blandingen ble deretter tilbakeløpskokt i én time og omrørt ved romtemperatur i
16 timer.
Deretter ble 29 ml vann tilsatt, den organiske fase ble skilt fra og den vandige fase ble ekstrahert med eter. De samlede organiske faser ble tørket med MgS04 og løsemidlet ble avdrevet under redusert trykk. Det ble oppnådd 52,1 g av et oljeaktig råprodukt som straks ble omsatt videre
Eksempel 2
2-Hydroksy-3,3-difenylbutyronitril
42,3 g (0,201 mol) 2,2-difenylpropionaldehyd ble oppløst i 230 ml TH F og 41,4 g (0,217 mol) p-toluensulfonsyre ble tilsatt. Deretter ble 14,09 g (0,217 mol) KCN i 60 ml vann tilsatt dråpevis. Blandingen ble deretter oppvarmet på 40°C i 3 timer. Reaksjonsblandingen ble konsentrert til omtrent 30% under redusert trykk, tatt opp i vann og ekstrahert tre ganger med etylacetat. De samlede organiske faser ble vasket to ganger med natriumdisulfittløsning, tørket over MgS04 og konsentrert under redusert trykk. Råproduktet ble kromatografert på silikagel med n-heptan/etylacetat (20:1). Det ble oppnådd 41,2 g (86%) 2-hydroksy-3,3-difenylbutyronitril.
<1>H-NMR[CDCI3],
5= 1,9 (s, 3H);2,7(d, 1H);5,1 (d, 1H); 7,2 - 7,4 (m, 10H)
Eksempel 3
Etyl-2-hydroksy-3,3-difenylbutyrat
1,0 g (4,2 mmol) 2-hydroksy-3,3-difenylbutyronitril ble oppløst i 10 ml etanol og 10 ml kons. HCI ble tilsatt. Blandingen ble tilbakeløpskokt i 24 timer og deretter ble løsemidlet avdrevet under redusert trykk og resten ble tatt opp i vann og ekstrahert to ganger med etylacetat. De samlede organiske faser ble vasket med 10% NaOH, tørket over MgS04 og konsentrert under redusert trykk. 0,8 g (67%) produkt ble oppnådd.
<1>H-NMR[CDCI3],
8 = 0,9 (t, 3H); 1,8 (s, 3H); 3,0 (d, 1H); 3,9 (q, 2H); 5,0 (d, 1H); 7,1 - 7,4 (m, 10H)
Eksempel 4
2-Hydroksy-3,3-difenylbutyramid
10,0 g (42,2 mmol) 2-hydroksy-3,3-difenylbutyronitril ble oppløst i 500 ml metanol (abs.) og det ble ved 5 - 10°C ført inn HCI i 3 timer. Blandingen ble deretter omrørt ved 5°C i 3 timer og ved romtemperatur i 16 timer. Deretter ble 200 ml 6 molar HCI tilsatt og blandingen ble inndampet til tørrhet under redusert trykk. Råproduktet ble omkrystallisert fra en etylacetat/heptan-blandjng. 2,5 g (23%) 2-hydroksy-3,3-difenylbutyramid ble oppnådd som et hvitt, fast stoff.
Eksempel 5
Etyl-2-hydroksy-3,3-difenylbutyrat
2,15 g (8,4 mmol) 2-hydroksy-3,3-difenylbutyramid ble oppløst i 15 ml etanol, 15 ml kons. HCI ble tilsatt og blandingen ble tilbakeløpskokt i 40 timer. Løsemidlet ble avdrevet under redusert trykk og resten ble tatt opp i vann. Den vandige fase ble ekstrahert tre ganger med etylacetat og de samlede organiske faser ble vasket to ganger med 10% natriumhydroksydløsning. Tørring med MgS04 og avdriving av løsemidlet under redusert trykk resulterte i 1,75 g (73%) etyl-2-hydroksy-3,3-difenylbutyrat.
Eksempel 6
2-Hydroksy-3,3-difenylsmørsyre
1,75 g (6,2 mmol) etyl-2-hydroksy-3,3-difenylbutyrat ble oppløst i 10 ml TH F og en oppløsning av 0,23 g (9,3 mmol) LiOH i 6 ml vann ble tilsatt. Blandingen ble omrørt ved romtemperatur i 16 timer og ved 40°C i 4 timer. Blandingen ble deretter konsentrert under redusert trykk, tatt opp i vann og vasket med etylacetat. Dette ble etterfulgt av surgjøreing med HCI og ekstraksjon tre ganger med etylacetat. De samlede etylacetatfaser ble tørket over MgS04 og løsemidlet ble avdrevet under redusert trykk. Resten ble kromatografert på silikagel med CH2CI2/MeOH (2:1). 0,80 g (50%) 2-hydroksy-3,3-difenylsmørsyre ble oppnådd.
<1>H-NMR[DMSO-d6],
5= 1,75 (s,3H); 4,85 (s, 1H); 5,5 (s, bred, 1H)); 7,1-7,4 (m, 10H), 12,2 (s, bred, 1H)
Eksempel 7
2-(4,6-Dimetyl-2-pyrimidinyloksy)-3,3-difenylsmørsyre
0,29 g (9,5 mmol) NaH ble anbrakt i DMF, og under nitrogen ble 0,80 g (3,15 mmol) 2-hydroksy-3,3-difenylsmørsyre i 3 ml DMF ble tilsatt. Etter omrøring ved romtemperatur i 30 minutter ble 0,45 g (3,15 mmol) 4,6-dimetyl-1,2-klor-pyrimidin i 4 ml DMF tilsatt og blandingen ble omrørt ved romtemperatur (RT) i 16 timer. Etter at løsemidlet var blitt avdrevet under redusert trykk ble resten tatt opp i vann, surgjort med HCI og ekstrahert to ganger med etylacetat. De samlede organiske faser ble tørket over MgSCv og løsemidlet ble avdrevet under redusert trykk. Resten ble kromatografert på silikagel med CH2CI2/metanol (10:1). 0,37 g (32%) 2-(4,6-dimetyl-2-pyrimidinyloksy)-3,3-difenyl-smørsyre med smeltepunkt 225-230°C ble oppnådd. <1>H-NMR[DMSO-d6],
6 = 1,95 (s, 3H); 2,3 (s, 6H); 5,95 (s, 1H)); 6,8 (s, 1H); 7,0 - 7,45 (m, 10 H)
Forbindelsen ble fraksjonert i sine to enantiomerer ved racematspalting (se Tabell 2).
Eksempel 8
Mety l-2-hyd roksy-3,3-d ifenylbutyrat
15,0 g (63,3 mmol) 2-hydroksy-3,3-difenylbutyronitril ble oppløst i 250 ml absolutt metanol og ved 30 - 50°C ble HCI ført inn inntil metning. Blandingen ble deretter tilbakeløpskokt i 72 timer og deretter konsentrert under redusert trykk og resten ble tatt opp i vann. Den vandige fase ble ekstrahert tre ganger med etylacetat; de samlede organiske faser ble tørket over MgS04, løsemidlet ble avdrevet under redusert trykk og resten ble kromatografert på silikagel med n-heptan/etylacetat (20:1). 1,2 g (7%) metyl-2-hydroksy-3,3-difenylbutyrat ble oppnådd. <1>H-NMR[CDCI3]
8 = 1,8 (s, 3H); 2,95 (d, 1H); 3,45 (s, 3H)); 5,0 (d, 1H); 7,1 - 7,4 (m, 10 H)
Eksempel 9
Metyl-2-(4,6-dimetoksy-2-pyrimidinyloksy)-3,3-d ifenylbutyrat
1,2 g (4,4 mmol) metyl-2-hydroksy-3,3-difenylbutyrat ble oppløst i 10 ml absolutt DMF og under nitrogen ble 1,2 g (8,8 mmol) K2C03 og 0,97 g (4,4 mmol) 2-_ metansulfonyl-4,6-dimetoksypyrimidin tilsatt. Blandingen ble omrørt ved romtemperatur i 16 timer. Den ble deretter inndampet og resten ble tatt opp i vann og
ekstrahert tre ganger med etylacetat. De samlede organiske faser ble tørket over MgSCv og konsentrert. 1,8 g råprodukt ble oppnådd og ble omsatt videre uten rensing.
<1>H-NMR [CDCb]
6 = 2,0 (s, 3H); 3,25 (s, 3H); 3,9 (s, 6H)); 5,75 (d, 1H); 5,8 (s, 1H); 7,1 -7,3 (m, 10H)
Eksempel 10
2-(4,6-Dimetoksy-2-pyrimidinyloksy)-3,3-difenylsmørsyre
1,8 g (4,4 mmol) metyl-2-(4,6-dimetoksy-2-pyrimidinyl-oksy)-3,3-difenylbutyrat ble oppløst i 25 ml dioksan og 26,5 ml (26,5 mmol) av en 1M KOH-løsning ble tilsatt og blandingen ble omrørt ved 90°C i 6 timer. Blandingen ble deretter konsentrert, tatt opp i vann og ekstrahert tre ganger med etylacetat. De samlede organiske faser ble tørket over MgS04 og inndampet. Resten ble omkrystallisert fra etanol. 1,12 g (65%) 2-(4,6-dimetoksy-2-pyrimidinyloksy)-3,3-difenyl-smørsyre med smeltepunkt 229-234°C ble oppnådd.
<1>H-NMR [DMSO-d6]
5= 1,9 (s, 3H); 3,85 (s, 6H); 5,85 (s, 1H)); 5,95 (s, 1H); 7,1-7,4 (m, 10H); 12,5 (s, bred, 1H)
Eksempel 11
2,2-Difenylbutyronitril
173 ml (0,259 mol) av en 1,5 M løsning av LDA i THF ble tilsatt dråpevis til en oppløsning av 50,0 g (0,259 mol) difenylacetonitril i 500 ml THF (abs.) ved -78°C under argon, og blandingen ble deretter omrørt ved -30°C i én time. Deretter ble det ved -78°C tilsatt 28,23 g (0,259 mol) etylbromid. Blandingen fikk nå romtemperatur og ble omrørt i 16 timer. Deretter ble 80 ml fosfatbuffer (pH 7) tilsatt og blandingen ble inndampet. Resten ble tatt opp i vann og ekstrahert tre ganger med etylacetat. De samlede organiske faser ble tørket over MgS04 og løsemidlet ble avdrevet under redusert trykk. Råproduktet ble kromatografert på silikagel med n-heptan/eddiksyre (20:1). 38,2 g (67%) 2,2-difenylbutyronitril ble oppnådd.
Eksempel 12
2,2-Difenylbutyraldehyd
21,1 g (95 mmol) 2,2-difenylbutyronitril ble oppløst i 100 ml toluen og ved - 78°C under nitrogen ble 95 ml (95 mmol) av en 1 M løsning av diisobutyl-aluminumhydrid tilsatt dråpevis. Blandingen ble deretter omrørt ved romtemperatur i 16 timer og deretter ble 60 ml en blanding av mettet ammoniumkloridløsning og 2 N
H2S04 i forholdet 2:1 tilsatt, og blandingen ble omrørt i 30 minutter. Fasene ble separert og den vandige fase ble ekstrahert tre ganger med etylacetat. De samlede organiske faser ble tørket over MgS04 og konsentrert under redusert trykk. Råproduktet ble kromatografert på silikagel med diklormetan. 19,0 g (89%) 2,2-, difenylbutyraldehyd ble oppnådd som en lys olje.
Eksempel 13
2-Hydroksy-3,3-difenylvaleronitril
17,4 g (91,6 mmol) p-toluensulfonsyre H20 og deretter 5,9 g (91,6 mmol) KCN i 25 ml vann, ble ved 35°C satt til en oppløsning av 19,09 g (84,8 mmol) 2,2-difenylbutyraldehyd i 97 ml THF (abs.). Blandingen ble deretter omrørt ved 40°C i 4 timer og ved romtemperatur i 16 timer. Blandingen ble inndampet til 1/3 av volumet, vann ble tilsatt og fasene ble separert. Den vandige fase ble deretter ekstrahert tre ganger med etylacetat og de samlede organiske faser ble vasket med 10% natriumdisulfittløsning, tørket over MgS04 og konsentrert under redusert trykk. Råproduktet ble kromatografert på silikagel med n-heptan/eddiksyre (20:1). 19,5 g (92%) 2-hydroksy-3,3-difenylvaleronitril ble oppnådd som en lys olje.
<1>H-NMR [CDCI3]
5 = 0,7 (t, 3H); 2,2 - 2,5 (m, 3H); 5,25 (d, 1H); 7,1 - 7,4 (m, 10 H)
Eksempel 14
2-(4,6-Dimetoksy-2-pyrimidinyloksy)-3,3-difenylvaleronitril
7,0 g (27,9 mmol) 2-hydroksy-3,3-difenylvaleronitril ble oppløst i 100 ml DMF (abs.) og under nitrogen ble 7,57 g (55,7 mmol) kaliumkarbonat og 6,1 g (27,9 mmol) 2-metansulfonyl-4,6-dimetoksypyrimidin tilsatt, og blandingen ble omrørt ved romtemperatur i 72 timer. Blandingen ble konsentrert under redusert trykk og resten ble tatt opp i vann og ekstrahert tre ganger med etylacetat. De samlede organiske faser ble tørket over MgS04 og løsemidlet ble avdampet. Råproduktet ble kromatografert på silikagel med n-heptan/etylacetat (20:1). 8,8 g (81%) produkt ble oppnådd.
<1>H-NMR[CDCI3]
5 = 0,8 (t, 3H); 2,45 (dq, 2H); 3,95 (s, 6H), 5,8 (s, 1H); 6,25 (s, 1H); 7,2-7,4 (m, 10 H)
Eksempel 15 2-(4,6-Dimetoksy-2-pyrimidinyloksy)-3,3-difenylvaleriansyre
0,5 g (1,3 mmol) 2-(4,6-dimetoksy-2-pyrimidinyl-oksy)-3,3-difenylvaleronitril ble oppløst i 5 ml etanol og etter tilsetning av 5 ml kons. HCI ble blandingen tilbakeløpskokt i 3 timer. Blandingen ble deretter konsentrert under redusert trykk og resten ble tatt opp i vann og ekstrahert to ganger med etylacetat. De samlede etylacetatfaser ble tørket over MgS04 og inndampet. Resten ble kromatografert ved hjelp av MPLC på reversfasemateriale med acetonitril/vann som eluent. 0,17 g (32%) 2-(4,6-dimetoksy-2-pyrimidinyloksy)-3,3-difenylvaleransyre med smeltepunkt 78-87°C ble oppnådd.
<1>H-NMR [DMSO-de]
5 = 0,7 (t, 3H); 2,2-2,55 (m, 2H); 3,85 (s, 6H); 5,9 (s, 2H), 70-74 (m, 10H);
12,7 (s, bred, 1H)
De eksempler som er angitt i den følgende tabell 1 kan fremstilles ved hjelp av de innledningsvis beskrevne fremgangsmåter:
Eksempel 16
Reseptorbindingsdata er målt ved hjelp av bindingstesten beskrevet i det foregående for forbindelsene angitt nedenfor.
Resultatene er vist i Tabell 2.
Claims (7)
1. a-Hydroksykarboksylsyre-derivater med formel I
karakterisert ved at R står for en gruppe
hvor R<1> betyr en rest OR<10>, hvor R<10> er: hydrogen, kationet av et alkalimetall så som litium, natrium, kalium, eller
kationet av et jordalkalimetall så som kalsium, magnesium og barium, samt fysiologisk akseptabelt alkylammoniumion eller ammoniumionet, C3-C8-cykloalkyl; Ci-C8-alkyl; CH2-fenyl, W betyr nitrogen;R<2> er CrC4-alkyl, Ci-C4-alkoksy, X er nitrogen eller CH;R<3> kan være hydrogen, CrC4 - alkyl, CrC4 - alkoksy eller CF3; og R2 og R<3> kan
være like eller forskjellige; Y er nitrogen; R<4> er fenyl; R<5> kan ha den samme betydning som R<4>; R<6> er eventuelt med hydroksy substituert CrC8-alkyl, eller
2. a-Hydroksykarboksylsyre-derivater ifølge krav 1,
karakterisert ved at R betyr COOH.
3. a-Hydroksykarboksylsyre-derivater ifølge et av de foregående krav, karakterisert ved at R6 betyr C-i-Ca-alkyl, eventuelt substituert med OH.
4. a-Hydroksykarboksylsyre-derivater ifølge et av de foregående krav, karakterisert ved at X betyr CH.
5. (x-Hydroksykarboksylsyre-derivater ifølge et av de foregående krav, karakterisert ved at minst én av restene R2, R<3> betyr Ci-C4-alkyl.
6. Anvendelse av forbindelser ifølge krav 1 - 5 for fremstilling av medikamenter for behandling av hypertoni, pulmonalt høytrykk, aktutt og kronisk nyresvikt, kronisk hjertesvikt, cerebral ischemi, restenose etter angioplasti, prostatakreft.
7. Anvendelse av en kombinasjon av en forbindelse ifølge krav 1-5 med en renin-angiotensin-system (RAS) -inhibitor for fremstilling av medikamenter for behandling av hypertoni, pulmonalt høytrykk, aktutt og kronisk nyresvikt, kronisk hjertesvikt, cerebral ischemi, restenose etter angioplasti, prostatakreft.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19614533A DE19614533A1 (de) | 1996-04-12 | 1996-04-12 | Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung |
PCT/EP1997/001688 WO1997038981A1 (de) | 1996-04-12 | 1997-04-04 | NEUE α-HYDROXYSÄUREDERIVATE, IHRE HERSTELLUNG UND VERWENDUNG |
Publications (3)
Publication Number | Publication Date |
---|---|
NO984717L NO984717L (no) | 1998-10-09 |
NO984717D0 NO984717D0 (no) | 1998-10-09 |
NO311801B1 true NO311801B1 (no) | 2002-01-28 |
Family
ID=7791117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19984717A NO311801B1 (no) | 1996-04-12 | 1998-10-09 | Nye hydroksykarboksylsyre-derivater og deres anvendelse |
Country Status (25)
Country | Link |
---|---|
US (1) | US6686369B1 (no) |
EP (1) | EP0892787B1 (no) |
JP (1) | JP2000508326A (no) |
KR (1) | KR20000005369A (no) |
AR (1) | AR007767A1 (no) |
AT (1) | ATE242770T1 (no) |
AU (1) | AU731579B2 (no) |
BG (1) | BG102868A (no) |
BR (1) | BR9708608A (no) |
CA (1) | CA2250757A1 (no) |
CO (1) | CO4900040A1 (no) |
DE (2) | DE19614533A1 (no) |
HR (1) | HRP970198A2 (no) |
HU (1) | HUP9901312A3 (no) |
ID (1) | ID16501A (no) |
IL (1) | IL126350A0 (no) |
NO (1) | NO311801B1 (no) |
NZ (1) | NZ332096A (no) |
PL (1) | PL329241A1 (no) |
SK (1) | SK134498A3 (no) |
TR (1) | TR199802039T2 (no) |
TW (1) | TW425383B (no) |
UA (1) | UA49884C2 (no) |
WO (1) | WO1997038981A1 (no) |
ZA (1) | ZA973097B (no) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20000057642A (ko) | 1996-12-18 | 2000-09-25 | 스타르크, 카르크 | 헤테로시클릭 카르복실산 유도체, 그의 제제 및 엔도텔린 수용체길항제로서의 용도 |
US6030975A (en) * | 1997-03-14 | 2000-02-29 | Basf Aktiengesellschaft | Carboxylic acid derivatives, their preparation and use in treating cancer |
DE19726146A1 (de) * | 1997-06-19 | 1998-12-24 | Basf Ag | Neue ß-Amino und ß-Azidopcarbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten |
NZ502642A (en) * | 1997-07-03 | 2002-06-28 | Du Pont Pharm Co | Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders |
DE19743681A1 (de) * | 1997-10-02 | 1999-04-08 | Knoll Ag | Methode zur Verhinderung der Transplantatabstoßung |
DK1023067T4 (da) | 1997-10-17 | 2011-12-12 | Ark Therapeutics Ltd | Anvendelse af inhibitorer af renin-angiotensin-systemet til behandling af hypoxi eller svækket metabolisk funktion |
DE19806438A1 (de) * | 1998-02-17 | 1999-08-19 | Basf Ag | Neue Carbonsäurederivate mit 5-substituiertem Pyrimidinring, ihre Herstellung und Verwendung |
US6124463A (en) * | 1998-07-02 | 2000-09-26 | Dupont Pharmaceuticals | Benzimidazoles as corticotropin release factor antagonists |
US6365589B1 (en) | 1998-07-02 | 2002-04-02 | Bristol-Myers Squibb Pharma Company | Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists |
US7566452B1 (en) | 1999-05-04 | 2009-07-28 | New York University | Cancer treatment with endothelin receptor antagonists |
DE10064797A1 (de) * | 2000-12-22 | 2002-06-27 | Knoll Ag | Orale und parenterale pharmazeutische Formulierung, umfassend eine niedermolekulare Thrombininhibitor-Pro-Pharmakon |
DK1243262T3 (da) | 2001-03-20 | 2006-10-02 | Sanol Arznei Schwarz Gmbh | Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter |
EP1243263B1 (en) | 2001-03-21 | 2002-11-27 | Schwarz Pharma Ag | Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain |
KR20070007931A (ko) | 2004-04-16 | 2007-01-16 | 쉬바르츠파르마에이지 | 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도 |
EP1604656A1 (en) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS) |
EA014055B1 (ru) | 2004-08-27 | 2010-08-30 | Шварц Фарма Аг | Применение пептидных соединений для лечения боли при раке кости, а также боли, вызванной химиотерапией и нуклеозидами |
US20100022568A1 (en) * | 2006-04-13 | 2010-01-28 | Actelion Pharmaceeuticals Ltd. | Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis |
TWI397417B (zh) | 2006-06-15 | 2013-06-01 | Ucb Pharma Gmbh | 具有協同抗驚厥功效之醫藥組成物 |
WO2011022694A2 (en) * | 2009-08-20 | 2011-02-24 | University Of Tennessee Research Foundation, The | Furanopyrimidine cannabinoid compounds and related methods of use |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4035758A1 (de) * | 1990-11-08 | 1992-05-14 | Schering Ag | Substituierte (alpha)-pyrimidinyloxy(thio)- und (alpha)-triazinyloxy(thio)-carbonsaeurederivate, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider, fungizider und pflanzenwachstumsregulierender wirkung |
DE4313412A1 (de) | 1993-04-23 | 1994-10-27 | Basf Ag | 3-(Het)aryl-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung |
DE4411225A1 (de) | 1994-03-31 | 1995-10-05 | Basf Ag | Verwendung von Carbonsäurederivaten als Arzneimittel |
DE19533023B4 (de) * | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
-
1996
- 1996-04-12 DE DE19614533A patent/DE19614533A1/de not_active Withdrawn
-
1997
- 1997-04-04 CA CA002250757A patent/CA2250757A1/en not_active Abandoned
- 1997-04-04 BR BR9708608A patent/BR9708608A/pt not_active IP Right Cessation
- 1997-04-04 AT AT97918110T patent/ATE242770T1/de not_active IP Right Cessation
- 1997-04-04 HU HU9901312A patent/HUP9901312A3/hu unknown
- 1997-04-04 JP JP9536699A patent/JP2000508326A/ja active Pending
- 1997-04-04 KR KR1019980708091A patent/KR20000005369A/ko not_active Application Discontinuation
- 1997-04-04 EP EP97918110A patent/EP0892787B1/de not_active Expired - Lifetime
- 1997-04-04 US US09/155,944 patent/US6686369B1/en not_active Expired - Fee Related
- 1997-04-04 NZ NZ332096A patent/NZ332096A/xx unknown
- 1997-04-04 PL PL97329241A patent/PL329241A1/xx unknown
- 1997-04-04 SK SK1344-98A patent/SK134498A3/sk unknown
- 1997-04-04 DE DE59710272T patent/DE59710272D1/de not_active Expired - Fee Related
- 1997-04-04 UA UA98116020A patent/UA49884C2/uk unknown
- 1997-04-04 WO PCT/EP1997/001688 patent/WO1997038981A1/de not_active Application Discontinuation
- 1997-04-04 IL IL12635097A patent/IL126350A0/xx unknown
- 1997-04-04 TR TR1998/02039T patent/TR199802039T2/xx unknown
- 1997-04-04 AU AU26365/97A patent/AU731579B2/en not_active Ceased
- 1997-04-11 AR ARP970101460A patent/AR007767A1/es not_active Application Discontinuation
- 1997-04-11 HR HR19614533.3A patent/HRP970198A2/xx not_active Application Discontinuation
- 1997-04-11 CO CO97018892A patent/CO4900040A1/es unknown
- 1997-04-11 ZA ZA973097A patent/ZA973097B/xx unknown
- 1997-04-12 TW TW086104727A patent/TW425383B/zh not_active IP Right Cessation
- 1997-04-14 ID IDP971242A patent/ID16501A/id unknown
-
1998
- 1998-10-09 NO NO19984717A patent/NO311801B1/no not_active IP Right Cessation
- 1998-10-26 BG BG102868A patent/BG102868A/bg unknown
Also Published As
Publication number | Publication date |
---|---|
HUP9901312A3 (en) | 2000-06-28 |
TR199802039T2 (xx) | 1999-01-18 |
NZ332096A (en) | 2000-01-28 |
HRP970198A2 (en) | 1998-04-30 |
WO1997038981A1 (de) | 1997-10-23 |
PL329241A1 (en) | 1999-03-15 |
ID16501A (id) | 1997-10-02 |
DE19614533A1 (de) | 1997-10-16 |
NO984717L (no) | 1998-10-09 |
ATE242770T1 (de) | 2003-06-15 |
HUP9901312A2 (hu) | 1999-08-30 |
EP0892787A1 (de) | 1999-01-27 |
CA2250757A1 (en) | 1997-10-23 |
ZA973097B (en) | 1998-10-12 |
KR20000005369A (ko) | 2000-01-25 |
DE59710272D1 (de) | 2003-07-17 |
AU2636597A (en) | 1997-11-07 |
EP0892787B1 (de) | 2003-06-11 |
US6686369B1 (en) | 2004-02-03 |
SK134498A3 (en) | 1999-03-12 |
JP2000508326A (ja) | 2000-07-04 |
BG102868A (bg) | 1999-11-30 |
AU731579B2 (en) | 2001-04-05 |
NO984717D0 (no) | 1998-10-09 |
CO4900040A1 (es) | 2000-03-27 |
BR9708608A (pt) | 1999-08-03 |
UA49884C2 (uk) | 2002-10-15 |
IL126350A0 (en) | 1999-05-09 |
AR007767A1 (es) | 1999-11-24 |
TW425383B (en) | 2001-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO311801B1 (no) | Nye hydroksykarboksylsyre-derivater og deres anvendelse | |
NO311025B1 (no) | Aminosyrederivater, legemiddel inneholdende dem og anvendelse som endotelinantagonister | |
KR20000068446A (ko) | 아지닐옥시, 및 페녹시-디아릴-카르복실산 유도체, 그의 제조 방법 및 혼합된 eta/etb 엔도델린 수용체 길항물질로서의 용도 | |
NO310497B1 (no) | Pyrimidin- eller triazin-karboksylsyrederivater, hvilke kan anvendes som legemidler | |
NO311802B1 (no) | Nye karboksylsyre-derivater og deres anvendelse | |
HRP980560A2 (en) | New carboxylic acid derivatives, carrying amido side-chains, their production and use as endothelin receptor antagonists | |
JP2001506243A (ja) | 複素環式カルボン酸誘導体、その製造およびエンドセリン受容体拮抗物質としての使用 | |
HRP980331A2 (en) | New beta-amino and beta-azido carboxylic acid derivatives, the production and the use thereof as endothelin receptor antagonists | |
JP2001514254A (ja) | 新規カルボン酸誘導体、その製造及び混合eta/etbエンドセリン受容体拮抗薬としてのその使用 | |
SK11512000A3 (sk) | 5-substituované deriváty pyrimidín-2-yloxy karboxylových kyselín, ich príprava a ich využitie ako antagonistov endotelínu | |
NO310651B1 (no) | Karboksylsyrederivater | |
TW555749B (en) | Novel carboxylic acid derivatives with 4,5-substituted pyrimidine ring, their preparation and pharmaceutical preparation comprising the same | |
JP2001523671A (ja) | 新規の置換α−ヒドロキシカルボン酸誘導体、その製造方法およびエンドセリンレセプターアンタゴニストとしての使用 | |
AU765345B2 (en) | Novel carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their production and their use as endothelin receptor antagonists | |
MXPA00006463A (en) | 5-substituted pyrimidine-2-yloxy carboxylic acid derivatives, the production of the same and their utilization as endothelin antagonists | |
JP2002505324A (ja) | 不斉に置換された新規のカルボン酸誘導体、その製造方法ならびに混合eta/etb受容体アンタゴニストとしての使用 | |
CA2340167A1 (en) | New carboxylic acid derivatives carrying keto side-chains, their production and their use as endothelin-receptor antagonists | |
CZ326198A3 (cs) | Nové deriváty alfa-hydroxy kyseliny, jejich příprava a použití | |
MXPA00001479A (en) | Novel carboxylic acid derivatives, their production and their use as mixed eta | |
HRP970503A2 (en) | Novel carboxylic acid derivatives, their production and their use as mixed eta/etb receptor antagonists | |
MXPA00007417A (en) | Novel unsymmetrically substituted carboxylic acid derivatives, method for producing them, and their use as mixed eta | |
MXPA99001995A (en) | New derivatives of oxilic acid, its obtaining and use in quality of mixed antagonists of receivers eta / |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |
Free format text: LAPSED IN OCTOBER 2003 |